

Healthy Volunteers

**A Single Ascending Dose Study to Investigate the Safety, Tolerability, Immunogenicity and Pharmacokinetics of Intravenously Administered RO7126209 in Healthy Participants**

**Trial Status**  
Completed

**Trial Runs In**  
1 Countries

**Trial Identifier**  
NCT04023994 BP41192

---

*The source of the below information is the publicly available website ClinicalTrials.gov. It has been summarised and edited into simpler language.*

***Trial Summary:***

Study BP41192 is a randomized, adaptive, placebo-controlled parallel group study to investigate the safety, tolerability, immunogenicity and pharmacokinetics of single-ascending intravenous (IV) doses of RO7126209 in healthy participants. RO7126209 is being developed for the treatment of Alzheimer's Disease.

**Hoffmann-La Roche**  
Sponsor

**Phase 1**  
Phase

---

**NCT04023994 BP41192**  
Trial Identifiers

---

***Eligibility Criteria:***

**Gender**  
Male

**Age**  
≥18 Years & ≤ 40 Years

**Healthy Volunteers**  
Accepts Healthy Volunteers

---